Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4BP6
The NM_007294.4(BRCA1):āc.804C>Gā(p.Asn268Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000174 in 1,611,504 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.36096245).
BP6
Variant 17-43094727-G-C is Benign according to our data. Variant chr17-43094727-G-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 441285.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Benign=1, Uncertain_significance=5}.
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Mar 23, 2023
University of Washington Department of Laboratory Medicine, University of Washington
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: curation
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
Nov 16, 2023
Ambry Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The p.N268K variant (also known as c.804C>G), located in coding exon 9 of the BRCA1 gene, results from a C to G substitution at nucleotide position 804. The asparagine at codon 268 is replaced by lysine, an amino acid with similar properties. This alteration was detected in a cohort of 212 Italian ovarian cancer patients (Minucci A et al. Expert Rev Mol Diagn, 2015 Aug;15:1383-403). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1
May 15, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
a variant of uncertain significance was detected in the BRCA1 gene (c.804C>G). This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 268 of the BRCA1 protein (p.Asn268Lys). This variant is present in population databases (rs771076131, gnomAD 0.01%). This missense change has been observed in individual(s) with breast and ovarian cancer (PMID: 26306726, 29020660). ClinVar contains an entry for this variant (Variation ID: 441285). This amino acid position is not well conserved ( PhyloP=2.65) . In addition, this alteration is predicted to be tolerated by in silico analysis. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
Nov 01, 2022
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The frequency of this variant in the general population, 0.000099 (3/30418 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in an individual with ovarian cancer (PMID: 26306726 (2015)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary breast ovarian cancer syndrome Uncertain:1
Mar 19, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 268 of the BRCA1 protein (p.Asn268Lys). This variant is present in population databases (rs771076131, gnomAD 0.01%). This missense change has been observed in individual(s) with breast and ovarian cancer (PMID: 26306726, 29020660). ClinVar contains an entry for this variant (Variation ID: 441285). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 95%. Experimental studies have shown that this missense change does not substantially affect BRCA1 function (PMID: 32546644). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Familial cancer of breast Benign:1
Feb 09, 2024
MGZ Medical Genetics Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
ACMG codes applied following ENIGMA VCEP rules: BP1_STR, BS3 -
Gain of ubiquitination at N268 (P = 0.0011);Gain of ubiquitination at N268 (P = 0.0011);.;Gain of ubiquitination at N268 (P = 0.0011);.;Gain of ubiquitination at N268 (P = 0.0011);.;Gain of ubiquitination at N268 (P = 0.0011);